NO20084659L - Ko-krystall av C-glucosidderivat og L-prolin - Google Patents
Ko-krystall av C-glucosidderivat og L-prolinInfo
- Publication number
- NO20084659L NO20084659L NO20084659A NO20084659A NO20084659L NO 20084659 L NO20084659 L NO 20084659L NO 20084659 A NO20084659 A NO 20084659A NO 20084659 A NO20084659 A NO 20084659A NO 20084659 L NO20084659 L NO 20084659L
- Authority
- NO
- Norway
- Prior art keywords
- crystal
- proline
- glucoside derivative
- glucoside
- derivative
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 title abstract 2
- 229930182821 L-proline Natural products 0.000 title abstract 2
- 229960002429 proline Drugs 0.000 title abstract 2
- -1 1-benzothien-2-ylmethyl Chemical group 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006103711 | 2006-04-05 | ||
| PCT/JP2007/057597 WO2007114475A1 (fr) | 2006-04-05 | 2007-04-04 | Cocristal du derive de c-glycoside et de l-proline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20084659L true NO20084659L (no) | 2009-01-02 |
Family
ID=38563736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20084659A NO20084659L (no) | 2006-04-05 | 2008-11-04 | Ko-krystall av C-glucosidderivat og L-prolin |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8097592B2 (fr) |
| EP (1) | EP2009010A4 (fr) |
| JP (1) | JP5210154B2 (fr) |
| KR (2) | KR20120025001A (fr) |
| CN (1) | CN101443328B (fr) |
| AU (1) | AU2007232763B2 (fr) |
| BR (1) | BRPI0710581A2 (fr) |
| CA (1) | CA2649022C (fr) |
| IL (1) | IL194512A0 (fr) |
| MX (1) | MX2008012705A (fr) |
| NO (1) | NO20084659L (fr) |
| RU (1) | RU2408595C2 (fr) |
| TW (1) | TWI370818B (fr) |
| WO (1) | WO2007114475A1 (fr) |
| ZA (1) | ZA200809201B (fr) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2363941T3 (es) * | 2003-03-14 | 2011-08-19 | Astellas Pharma Inc. | Derivados de c-glucósido para el tratamiento de diabetes. |
| TW200726755A (en) * | 2005-07-07 | 2007-07-16 | Astellas Pharma Inc | A crystalline choline salt of an azulene derivative |
| TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| WO2008075736A1 (fr) | 2006-12-21 | 2008-06-26 | Astellas Pharma Inc. | Procédé de fabrication d'un dérivé de c-glycoside et intermédiaire de synthèse de celui-ci |
| UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
| ES2541141T3 (es) * | 2008-01-31 | 2015-07-16 | Astellas Pharma Inc. | Composición farmacéutica para el tratamiento de las enfermedades del hígado graso |
| CN103910702A (zh) * | 2008-08-22 | 2014-07-09 | 泰拉科斯有限公司 | 制备sglt2抑制剂的方法 |
| AU2009286380B2 (en) * | 2008-08-28 | 2011-09-15 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| MX2012004782A (es) * | 2009-10-23 | 2012-09-12 | Astellas Pharma Inc | Composicion farmaceutica para administracion oral. |
| RS53827B1 (sr) | 2009-11-02 | 2015-06-30 | Pfizer Inc. | Derivati dioksa-biciklo[3.2.1]oktan-2,3,4-triola |
| ES2689107T3 (es) | 2009-11-13 | 2018-11-08 | Astrazeneca Ab | Formulaciones de tabletas bicapa |
| EP2498759B1 (fr) | 2009-11-13 | 2018-08-01 | AstraZeneca AB | Formulations pour comprimés à libération immédiate |
| WO2011060255A1 (fr) | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Formulations de metformine a masse reduite |
| SG10201506114UA (en) | 2010-05-11 | 2015-09-29 | Janssen Pharmaceutica Nv | Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt |
| WO2011153712A1 (fr) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène |
| EP2611442B1 (fr) | 2010-09-03 | 2018-07-04 | Bristol-Myers Squibb Company | Formulations de médicament au moyen d'antioxydants hydrosolubles |
| WO2012041898A1 (fr) | 2010-09-29 | 2012-04-05 | Celon Pharma Sp. Z O.O. | Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète |
| US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| BR112013019026A2 (pt) | 2011-02-01 | 2016-10-04 | Astrazeneca Uk Ltd | formulações farmacêuticas incluindo um composto amina |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| WO2012116349A2 (fr) * | 2011-02-26 | 2012-08-30 | Amplio Pharma, Llc | Nouveaux cocristaux d'ézétimibe |
| EP2697218B1 (fr) | 2011-04-13 | 2016-05-25 | Janssen Pharmaceutica NV | Procédé pour la préparation de composés utiles en tant qu'inhibiteurs de sglt2 |
| KR101841087B1 (ko) * | 2011-04-22 | 2018-03-23 | 아스텔라스세이야쿠 가부시키가이샤 | 고형 의약 조성물 |
| TWI542596B (zh) * | 2011-05-09 | 2016-07-21 | 健生藥品公司 | （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體 |
| BR112013031032A2 (pt) | 2011-06-03 | 2016-11-29 | Boehringer Ingelheim Int | inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos |
| BR112014010574A2 (pt) * | 2011-10-31 | 2017-05-02 | Scinopharm Taiwan Ltd | formas cristalinas e não cristalinas de inibidores sglt2 |
| WO2013152476A1 (fr) | 2012-04-10 | 2013-10-17 | Theracos, Inc. | Procédé de préparation d'inhibiteurs de sglt2 benzylbenzène |
| ITMI20120586A1 (it) | 2012-04-11 | 2013-10-12 | Milano Politecnico | Co-cristalli di 3-iodiopropinil butilcarbammato |
| RU2497804C1 (ru) * | 2012-05-02 | 2013-11-10 | Федеральное государственное бюджетное учреждение науки институт химии растворов им. Г.А. Крестова Российской академии наук | Сокристаллическая форма 2-гидроксибензамида с 4-аминобензойной кислотой |
| US9145434B2 (en) * | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| EP2722327A1 (fr) * | 2012-10-22 | 2014-04-23 | Quantum Genomics | Phase cristalline de (3S, 3s') 4,4'-disulfanediylbis (acide 3-aminobutane 1-sulfonique) avec de la L-lysine |
| CN103910769B (zh) * | 2012-12-31 | 2018-10-02 | 上海璎黎药业有限公司 | 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用 |
| PT2981269T (pt) | 2013-04-04 | 2023-10-10 | Boehringer Ingelheim Vetmedica Gmbh | Tratamento de distúrbios metabólicos em animais equinos |
| CN104098572A (zh) * | 2013-04-08 | 2014-10-15 | 博瑞生物医药技术(苏州)有限公司 | 替卡格雷共晶型 |
| CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
| ES2969764T3 (es) | 2013-12-17 | 2024-05-22 | Boehringer Ingelheim Vetmedica Gmbh | Un inhibidor de SGLT-2 para usar en el tratamiento de un trastorno metabólico en animales felinos |
| CN103626710A (zh) * | 2013-12-20 | 2014-03-12 | 苏州晶云药物科技有限公司 | 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的共晶及其制备方法 |
| US9969701B2 (en) | 2013-12-20 | 2018-05-15 | Crystal Pharmatech Co., Ltd. | Salts and co-crystals of lesinurad |
| CN115671290A (zh) | 2014-01-23 | 2023-02-03 | 勃林格殷格翰动物保健有限公司 | 犬科动物中代谢紊乱的治疗 |
| WO2015150299A2 (fr) | 2014-04-01 | 2015-10-08 | Boehringer Ingelheim Vetmedica Gmbh | Traitement de troubles métaboliques chez les équidés |
| KR101613488B1 (ko) | 2014-06-18 | 2016-04-20 | (주) 디엔디이 | Mice 행사용 초대장 회답 통합관리시스템 |
| CN104017031A (zh) * | 2014-06-21 | 2014-09-03 | 李友香 | 降血糖药物和组合物 |
| CN104031098A (zh) * | 2014-06-21 | 2014-09-10 | 李友香 | 降糖药物 |
| WO2016046150A1 (fr) | 2014-09-25 | 2016-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Polythérapie avec des inhibiteurs de sglt2 et des agonistes de la dopamine utilisée pour la prévention des troubles métaboliques chez des équidés |
| KR102659761B1 (ko) | 2015-08-27 | 2024-04-24 | 베링거잉겔하임베트메디카게엠베하 | Sglt-2 억제제를 포함하는 액상 약제학적 조성물 |
| WO2017046730A1 (fr) | 2015-09-15 | 2017-03-23 | Laurus Labs Private Limited | Co-cristaux d'inhibiteurs de sglt2, procédé pour leur préparation et compositions pharmaceutiques de ceux-ci |
| CN106924206A (zh) * | 2015-12-31 | 2017-07-07 | 深圳翰宇药业股份有限公司 | 一种依格列净口服固体制剂及其制备方法 |
| BR112020011625A2 (pt) * | 2017-12-11 | 2020-11-17 | Artelo Biosciences, Inc. | formas sólidas de canabidiol e usos das mesmas |
| EP3784231A4 (fr) * | 2018-04-25 | 2022-05-11 | Theracos Sub, LLC | Méthodes de traitement de l'hypertension |
| KR102097250B1 (ko) | 2019-11-09 | 2020-04-03 | 유니셀랩 주식회사 | 신규한 이프라글리플로진의 결정형, 이의 제조방법 또는 용도 |
| EP4064854A1 (fr) | 2019-11-28 | 2022-10-05 | Boehringer Ingelheim Vetmedica GmbH | Utilisation d'inhibiteurs de sglt-2 dans le séchage de mammifères non humains |
| CN114980753A (zh) * | 2020-02-03 | 2022-08-30 | 雀巢产品有限公司 | 用于改善和维持儿童和青少年中葡萄糖代谢的组合物和方法 |
| AU2021222297B2 (en) | 2020-02-17 | 2026-01-22 | Boehringer Ingelheim Vetmedica Gmbh | Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines |
| CA3180674A1 (fr) | 2020-04-22 | 2021-10-28 | Bayer Aktiengesellschaft | Combinaison de finerenone et d'un inhibiteur de sglt2 pour le traitement et/ou la prevention de maladies cardiovasculaires et/ou renales |
| KR102660615B1 (ko) | 2020-10-28 | 2024-04-26 | 동방에프티엘(주) | 이프라글리플로진의 신규 공결정 및 이의 제조 방법 |
| CN113234028B (zh) * | 2021-04-29 | 2022-08-26 | 上海大学 | 一种5-氟尿嘧啶与肌氨酸的共晶体及其制备方法与用途 |
| US20240269105A1 (en) | 2021-07-28 | 2024-08-15 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
| JP2024527434A (ja) | 2021-07-28 | 2024-07-24 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | ネコ科動物を除く非ヒト哺乳動物、特にイヌ科動物における心臓疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用 |
| JP2024525981A (ja) | 2021-07-28 | 2024-07-12 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | ヒト以外の哺乳動物における腎疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用 |
| US20250170128A1 (en) | 2021-12-30 | 2025-05-29 | NEWAMSTERDAM PHARMA B.V. (Dutch Chamber of Commerce No. 5597 1946) | Obicetrapib and SGLT2 Inhibitor Combination |
| AU2023277704A1 (en) | 2022-05-25 | 2024-12-05 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
| KR20240044194A (ko) * | 2022-09-28 | 2024-04-04 | 주식회사 대웅제약 | 이나보글리플로진의 신규한 공결정 |
| EP4676494A1 (fr) | 2023-03-06 | 2026-01-14 | Boehringer Ingelheim Vetmedica GmbH | Systèmes d'administration de compositions pharmaceutiques liquides comprenant en particulier un ou plusieurs inhibiteurs de sglt-2 |
| TW202446389A (zh) | 2023-04-24 | 2024-12-01 | 荷蘭商新阿姆斯特丹製藥公司 | 非晶形奧比特拉(obicetrapib)與sglt2抑制劑之組合 |
| US20240390317A1 (en) | 2023-05-24 | 2024-11-28 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan |
| KR20260019532A (ko) | 2023-05-24 | 2026-02-10 | 베링거잉겔하임베트메디카게엠베하 | 하나 이상의 sglt-2 억제제와 텔미사르탄을 포함하는 비인간 포유류의 신장 질환 및/또는 고혈압의 병용 치료 및/또는 예방 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| AU2002254567B2 (en) * | 2001-04-11 | 2007-10-11 | Bristol-Myers Squibb Company | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method |
| ES2363941T3 (es) * | 2003-03-14 | 2011-08-19 | Astellas Pharma Inc. | Derivados de c-glucósido para el tratamiento de diabetes. |
| ES2531660T3 (es) | 2003-08-01 | 2015-03-18 | Mitsubishi Tanabe Pharma Corporation | Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio |
| NZ545133A (en) | 2003-09-04 | 2009-12-24 | Cephalon Inc | Modafinil compositions |
| TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| WO2008075736A1 (fr) | 2006-12-21 | 2008-06-26 | Astellas Pharma Inc. | Procédé de fabrication d'un dérivé de c-glycoside et intermédiaire de synthèse de celui-ci |
-
2007
- 2007-04-03 TW TW096111913A patent/TWI370818B/zh not_active IP Right Cessation
- 2007-04-04 JP JP2008508716A patent/JP5210154B2/ja active Active
- 2007-04-04 MX MX2008012705A patent/MX2008012705A/es active IP Right Grant
- 2007-04-04 US US12/296,056 patent/US8097592B2/en not_active Expired - Fee Related
- 2007-04-04 AU AU2007232763A patent/AU2007232763B2/en not_active Ceased
- 2007-04-04 KR KR1020127002361A patent/KR20120025001A/ko not_active Ceased
- 2007-04-04 BR BRPI0710581-9A patent/BRPI0710581A2/pt not_active IP Right Cessation
- 2007-04-04 WO PCT/JP2007/057597 patent/WO2007114475A1/fr not_active Ceased
- 2007-04-04 CN CN2007800169018A patent/CN101443328B/zh active Active
- 2007-04-04 EP EP07741033A patent/EP2009010A4/fr not_active Withdrawn
- 2007-04-04 CA CA2649022A patent/CA2649022C/fr not_active Expired - Fee Related
- 2007-04-04 RU RU2008143362/04A patent/RU2408595C2/ru not_active IP Right Cessation
- 2007-04-04 KR KR1020087027002A patent/KR101243039B1/ko active Active
-
2008
- 2008-10-02 IL IL194512A patent/IL194512A0/en not_active IP Right Cessation
- 2008-10-27 ZA ZA2008/09201A patent/ZA200809201B/en unknown
- 2008-11-04 NO NO20084659A patent/NO20084659L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200811152A (en) | 2008-03-01 |
| KR101243039B1 (ko) | 2013-03-20 |
| CA2649022C (fr) | 2012-05-29 |
| BRPI0710581A2 (pt) | 2011-08-16 |
| RU2008143362A (ru) | 2010-05-10 |
| EP2009010A4 (fr) | 2012-06-13 |
| AU2007232763A1 (en) | 2007-10-11 |
| MX2008012705A (es) | 2008-10-15 |
| CN101443328B (zh) | 2012-07-25 |
| CN101443328A (zh) | 2009-05-27 |
| KR20090015912A (ko) | 2009-02-12 |
| TWI370818B (en) | 2012-08-21 |
| ZA200809201B (en) | 2009-12-30 |
| EP2009010A1 (fr) | 2008-12-31 |
| JPWO2007114475A1 (ja) | 2009-08-20 |
| US20090143316A1 (en) | 2009-06-04 |
| KR20120025001A (ko) | 2012-03-14 |
| IL194512A0 (en) | 2009-08-03 |
| JP5210154B2 (ja) | 2013-06-12 |
| US8097592B2 (en) | 2012-01-17 |
| CA2649022A1 (fr) | 2007-10-11 |
| WO2007114475A1 (fr) | 2007-10-11 |
| AU2007232763B2 (en) | 2011-07-28 |
| RU2408595C2 (ru) | 2011-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20084659L (no) | Ko-krystall av C-glucosidderivat og L-prolin | |
| EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
| CL2008000946A1 (es) | Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun | |
| WO2007060140A3 (fr) | Inhibiteurs de diacylglycérol acyltransférase (dgat) | |
| MY149622A (en) | Pyrazoles as 11-beta-hsd-1 | |
| CL2011002697A1 (es) | Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes | |
| IL187005A0 (en) | Diacylglycerol acyltransferase inhibitors | |
| MX2009012285A (es) | Inhibidores de diacilglicerol aciltransferasa. | |
| AR062471A1 (es) | SESQUIHIDRATO CRISTALINO DEL TARTRATO DE 1-[2-FLUORO-4-(TRIFLUOROMETIL)-3-(3-{[4-METIL-5-(4-METIL-1, 3-OXAZOL-5-IL)-4H-1, 2, 4-TRIAZOL-3-IL]TIO}PROPIL)-3-AZABICICLO[3.1.0]HEXANO (1S, 5R) o (2R, 3R), SU USO PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA MODU | |
| WO2009010416A3 (fr) | Inhibiteurs de 11b-hydroxystéroïde déshydrogenase | |
| DK2150530T3 (da) | Substituerede sulfonamid-derivater | |
| NO20080865L (no) | Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer | |
| WO2007082808A3 (fr) | Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1 | |
| WO2007096151A3 (fr) | Composes organiques | |
| EA201070588A1 (ru) | Производные 1,2,3-триазола для применения в качестве ингибиторов стеароил-соа десатуразы | |
| MX2007010532A (es) | Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii. | |
| EA201000486A1 (ru) | Ингибитор белка, активирующего 5-липоксигеназу (flap) | |
| EA201070864A1 (ru) | Новые гетероциклические соединения | |
| NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
| NO20071314L (no) | Peptidiske vasopressinreseptoragonister | |
| GEP20094727B (en) | Oxyindole derivatives as 5ht4 receptor agonists | |
| BRPI0806789B8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| NO341679B1 (no) | Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren | |
| MX2007012212A (es) | 1h-pirazol 4-carboxilamidas, su preparacion y su uso como 11-beta-hidroxiesteroide deshidrogenasa. | |
| EP1714961A4 (fr) | Compos indazole et utilisation pharmaceutique de celui-ci |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |